|
MechanismIL-6RA antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date16 Oct 2024 |
A Multicenter, Randomized, Double-Blind, Parallel Group, Positive Drug Control Evaluation of the Efficacy and Safety of CMAB806 in Combination with Methotrexate for the Treatment of Adult Patients with Moderate to Severe Active Rheumatoid Arthritis
100 Clinical Results associated with Jinyu Bowo Runze Biotechnology Co., Ltd.
0 Patents (Medical) associated with Jinyu Bowo Runze Biotechnology Co., Ltd.
100 Deals associated with Jinyu Bowo Runze Biotechnology Co., Ltd.
100 Translational Medicine associated with Jinyu Bowo Runze Biotechnology Co., Ltd.